TY - JOUR
T1 - Downregulation of PRRX1 Confers Cancer Stem Cell-Like Properties and Predicts Poor Prognosis in Hepatocellular Carcinoma
AU - Hirata, Hidenari
AU - Sugimachi, Keishi
AU - Takahashi, Yusuke
AU - Ueda, Masami
AU - Sakimura, Shotaro
AU - Uchi, Ryutaro
AU - Kurashige, Junji
AU - Takano, Yuki
AU - Nanbara, Sho
AU - Komatsu, Hisateru
AU - Saito, Tomoko
AU - Shinden, Yoshiaki
AU - Iguchi, Tomohiro
AU - Eguchi, Hidetoshi
AU - Atsumi, Kazushige
AU - Sakamoto, Katsumi
AU - Doi, Toshiro
AU - Hirakawa, Masakazu
AU - Honda, Hiroshi
AU - Mimori, Koshi
N1 - Publisher Copyright:
© 2014, Society of Surgical Oncology.
PY - 2015/12/1
Y1 - 2015/12/1
N2 - Background: Downregulation of paired related homeobox 1 (PRRX1) is associated with the acquisition of cancer stem cell (CSC)-like properties and poor prognosis in cancers. The purpose of this study is to clarify the role of PRRX1 expression in predicting prognosis and mediating CSC-like properties in hepatocellular carcinoma (HCC). Methods: The association between PRRX1 expression and overall survival (OS) of patients with HCC was analyzed in three independent datasets: 62 resected primary cases, 242 cases from GSE14520, and 162 cases from The Cancer Genome Atlas (TCGA). A cell line expressing PRRX1 (HuH7) was established for the functional analyses. The ability to form spheres, the expression levels of the hepatic CSC surface markers (CD13, CD133, and EpCAM), in vitro chemosensitivity to 5-fluorouracil (FU), and radiosensitivity were evaluated. Results: Univariate and multivariate analyses showed that the 5-year OS of the low PRRX1 expression group was significantly poorer than that of the high PRRX1 expression group (P = 0.024 and P = 0.045, respectively). Consistent with this, the low PRRX1 expression group in GSE14520 and TCGA datasets showed significantly shorter OS (P = 0.027 and P = 0.010, respectively). Gene set enrichment analysis on GSE14520 and TCGA datasets indicated that downregulation of PRRX1 was correlated with the stemness signature. The number of spheres and the expression levels of CSC markers were significantly decreased when PRRX1 was expressed. Moreover, PRRX1 impaired resistance to 5-FU and radiation. Conclusions: Downregulation of PRRX1 expression contributes to the poor prognosis of patients with HCC through acquisition of CSC-like properties.
AB - Background: Downregulation of paired related homeobox 1 (PRRX1) is associated with the acquisition of cancer stem cell (CSC)-like properties and poor prognosis in cancers. The purpose of this study is to clarify the role of PRRX1 expression in predicting prognosis and mediating CSC-like properties in hepatocellular carcinoma (HCC). Methods: The association between PRRX1 expression and overall survival (OS) of patients with HCC was analyzed in three independent datasets: 62 resected primary cases, 242 cases from GSE14520, and 162 cases from The Cancer Genome Atlas (TCGA). A cell line expressing PRRX1 (HuH7) was established for the functional analyses. The ability to form spheres, the expression levels of the hepatic CSC surface markers (CD13, CD133, and EpCAM), in vitro chemosensitivity to 5-fluorouracil (FU), and radiosensitivity were evaluated. Results: Univariate and multivariate analyses showed that the 5-year OS of the low PRRX1 expression group was significantly poorer than that of the high PRRX1 expression group (P = 0.024 and P = 0.045, respectively). Consistent with this, the low PRRX1 expression group in GSE14520 and TCGA datasets showed significantly shorter OS (P = 0.027 and P = 0.010, respectively). Gene set enrichment analysis on GSE14520 and TCGA datasets indicated that downregulation of PRRX1 was correlated with the stemness signature. The number of spheres and the expression levels of CSC markers were significantly decreased when PRRX1 was expressed. Moreover, PRRX1 impaired resistance to 5-FU and radiation. Conclusions: Downregulation of PRRX1 expression contributes to the poor prognosis of patients with HCC through acquisition of CSC-like properties.
UR - http://www.scopus.com/inward/record.url?scp=84952870034&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84952870034&partnerID=8YFLogxK
U2 - 10.1245/s10434-014-4242-0
DO - 10.1245/s10434-014-4242-0
M3 - Article
C2 - 25404478
AN - SCOPUS:84952870034
SN - 1068-9265
VL - 22
SP - 1402
EP - 1409
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
ER -